Navigation Links
Enanta Announces Positive Phase 2 Results From Interferon-Free Combination Studies with ABT-450 for Hepatitis C Treatment to be Presented at EASL
Date:4/4/2012

WATERTOWN, Mass., April. 4, 2012 /PRNewswire/ --Enanta Pharmaceuticals, Inc., a research and development company dedicated to creating best-in-class small molecule drugs in the infectious disease field, announced today that key data from two of its hepatitis C (HCV) programs will be presented at the International Liver Congress™ 2012 (ILC2012), the annual meeting of the European Association for the Study of the Liver (EASL), April 18-22 in Barcelona, Spain.  Oral presentations will discuss Phase 2 results from "Pilot" and "Co-Pilot", which investigated two different interferon-free combination regimens containing ABT-450, the lead candidate from Enanta's collaborative HCV protease inhibitor program with Abbott.  ABT-450 will be included in two additional poster presentations and a third poster presentation will report in vitro data from Enanta's proprietary nucleotide HCV polymerase inhibitor program. Abstracts are available at www.easl.eu.  

Phase 2 Data Highlights

In the study known as "Co-Pilot," different doses of ABT-450/r, plus ABT-333 and ribavirin administered for 12 weeks showed sustained virological response at 12 weeks post treatment (SVR12) in 93 percent and 95 percent of treatment-naive genotype 1 (GT1) patients.  In these patients, response was independent of HCV subtype, host IL28B genotype or dose of ABT-450/r.  In addition, SVR12 was achieved in 47 percent of patients who were previous non-responders to past HCV treatment.

In a separate study, known as "Pilot", 91 percent of genotype 1 infected, treatment-naive patients taking ABT-450/r and ABT-072 combined with ribavirin administered for 12 weeks, achieved sustained viral response at 24 weeks (SVR24).

"The results from Pilot and Co-Pilot showed very encouraging levels of sustained response and suggest that ABT-450 could be an important component in new
'/>"/>

SOURCE Enanta Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
2. Enanta Initiates Phase 1 Study on EDP-322, an Oral Antibiotic With Activity Against Hospital- and Community-Acquired MRSA
3. Abbott and Enanta Initiate Phase 1 Clinical Trial on ABT-450 HCV Protease Inhibitor
4. Abbott and Enanta Present Positive Initial Results from Phase 2 Study of ABT-450/r for Treatment of Hepatitis C
5. Enanta Enters Into Strategic Collaboration to Advance NS5A Inhibitor Candidate for HCV
6. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
7. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
8. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
9. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
10. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
11. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... 31, 2015  Xcelience, a contract development and ... made a structured cash investment in Powdersize, a ... milling, micronization and powder size classification within the ... business while simultaneously adding a complete set of ... capabilities. "As we continue to ...
(Date:7/31/2015)... 2015  Xencor, Inc. (NASDAQ: XNCR ), a ... treatment of autoimmune diseases, asthma and allergic diseases, and ... Hata to its board of directors. ... development is a tremendous asset to our board," said ... officer of Xencor. "Xencor faces a range of opportunities ...
(Date:7/30/2015)... , July 30, 2015  ResMed (NYSE: ... signed a definitive agreement to acquire Curative ... ventilation and sleep-disordered breathing medical devices and ... market reputation in China, combined with ResMed,s global leadership in sleep and ... China suffering from ...
Breaking Medicine Technology:Xcelience Makes Structured Cash Investment in Powdersize 2Xcelience Makes Structured Cash Investment in Powdersize 3Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3
... Calif., Oct. 27 ... beamforming technology, analog-front-end semiconductors and solutions for the ... Ultrasound Beamforming Development Kit.  Based on Samplify,s AutoFocus™ ... solution for the ultrasound front end, from probe ...
... Oct. 27 Solos Endoscopy, Inc. (Pink Sheets: ... revenues during the three months ended September 30, 2010 in ... ended September 30, 2009.  This was an increase of 34.8% for ... Despite a down global economy, Solos has been able ...
Cached Medicine Technology:Samplify's New Medical Ultrasound Development Kit Accelerates Equipment Time to Market By Up to 12 Months 2Samplify's New Medical Ultrasound Development Kit Accelerates Equipment Time to Market By Up to 12 Months 3Solos Endoscopy, Inc. Revenue Grows 34.8% for Third Quarter 2010 2
(Date:7/31/2015)... ... ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company based in Seattle, ... it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to use a promising ... will grant 100% of the money raised to BioViva to help bring pioneering gene ...
(Date:7/31/2015)... Church, VA (PRWEB) , ... July 31, 2015 ... ... Way, Oct. 20-21, 2015 – Washington, DC, http://www.fdanews.com/importexportprogram , Having FDA-regulated ... it doesn’t have to. , Instead of risking containment — or even destruction ...
(Date:7/31/2015)... Tampa, FL (PRWEB) , ... July 31, 2015 ... ... cancer patients using the RenovoCath,™ a novel catheter that was developed for targeted ... locally-advanced pancreatic cancer are now being treated at Florida Hospital Tampa with the ...
(Date:7/31/2015)... ... July 31, 2015 , ... Ticket Down is a ... Birmingham. The U.S. Women's National Soccer Team will face the Australia Women's National Team ... September 17th at Ford Field in Detroit and the second match will occur in ...
(Date:7/31/2015)... ... ... Indosoft, Inc., is pleased to announce a major update to its agent interface ... ACD system for Asterisk-based call centers . The new features make it easier ... agent only when wanted, and allows for validation of data as the agent enters ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 2Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 3Health News:FDAnews Announces — Successful Import/Export Programs: Former FDA Expert Shows the Way, Oct. 20-21, 2015 4Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 2Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 3Health News:Florida Hospital Tampa Expands Treatment Options for Patients with Pancreatic Cancer Using New Catheter Technology 4Health News:Cheap USA vs. Australia Tickets at Legion Field in Birmingham, AL: Ticket Down Slashes Ticket Prices for Australia vs. USWNT at Legion Field 2Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2
... Accepts as Complete DNV,s ... Hospital Deeming Authority, HOUSTON, March 24 The U.S. ... that its application to,deem hospitals in compliance with the Medicare ... formal review., If approved, DNV stands to become the ...
... Control of all Sites from a Single ... ... Dayton,Ohio has chosen multiple products from Sage Software - including the,Intergy by ... and improve the,patient experience. Previously, Digestive Specialists used The Medical,Manager by Sage., ...
... March 24 MedCath Corporation,(MedCath) (Nasdaq: MDTH ... Ohio) jointly announced today that the parties have,entered ... Samaritan,Hospital will acquire substantially all of Dayton Heart ... $55.0 million, a portion of,which is allocated to ...
... they,re not getting needed screenings for breast and cervical tumors ... of 32 studies suggests that obese women -- particularly white ... for breast and cervical cancer. , No one knows ... mammograms or Pap smears. And it,s not known why obesity ...
... BOSTON, March 24 "Going head-to-head with your child,can be ... ask,for some extra reading at bedtime and, before you know ... that you can,t refuse.,Well, if I can,t stay up late ... I guess you owe me a back rub and two ...
... Joint ST/Veredus lab set up in Singapore to develop future lab-on-chip ... ... SINGAPORE, March 24 Following the,success of the evaluation trials conducted ... STM ) today announced the commercial availability,of VereFlu(TM), a portable ...
Cached Medicine News:Health News:DNV Healthcare Advances in Bid to Accredit Hospitals 2Health News:Multi-site Gastro Practice Chooses Intergy by Sage Practice Management System 2Health News:MedCath Enters Definitive Agreement to Sell Dayton Heart Hospital to Good Samaritan Hospital-Dayton 2Health News:MedCath Enters Definitive Agreement to Sell Dayton Heart Hospital to Good Samaritan Hospital-Dayton 3Health News:Obese Women Less Likely to Be Tested for Some Cancers 2Health News:HOW TO UNSPOIL YOUR CHILD FAST: Harvard Medical School Psychologist Writes Book to Guide and Motivate Parents and Support the Children's Defense Fund 2Health News:STMicroelectronics and Veredus Laboratories Launch Market's First Lab-on-Chip for Rapid Molecular Flu Detection at Point of Need 2Health News:STMicroelectronics and Veredus Laboratories Launch Market's First Lab-on-Chip for Rapid Molecular Flu Detection at Point of Need 3
Illuminated Phoroptor Refracting Instrument. Illumination is provided by a cool-running, energy efficient LEDs (Light Emitting Diodes) that light only what you need to see without affecting the darke...
Red Lens Maddox...
The Snellen chart is the default optotype with the standard order of letters (T Z V E C L) as default. When the Refresh 'R' button is pressed, the letters ( or pictures ) are replaced with a random s...
Snellen 20' Eye Test Chart....
Medicine Products: